Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cytarabine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43691   clinical trials with a EudraCT protocol, of which   7246   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    125 result(s) found for: Cytarabine. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2015-004896-60 Sponsor Protocol Number: LUMC2015-02 Start Date*: 2015-11-26
    Sponsor Name:Leiden University Medical Center
    Full Title: Decitabine-cytarabine chemotherapy in elderly AML and high risk MDS patients (> 65 years) with high early mortality risk
    Medical condition: Acute myeloid leukemia and high risk myelodysplasia
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002345-39 Sponsor Protocol Number: Göteborg University Start Date*: 2006-02-16
    Sponsor Name:NOPHO NHL-group
    Full Title: B-NHL BFM 04
    Medical condition: B-cell lymphoma or B-ALL in children up to 18 years of age
    Disease:
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000699-24 Sponsor Protocol Number: PHRC2010-03 Start Date*: 2014-10-02
    Sponsor Name:CHU Angers-DAMR
    Full Title: Essai de phase 3 visant à améliorer la survie globale des LAM de l’adulte de 18 à 60 ans en comparant l’idarubicine à forte dose à la daunorubicine à l’induction, la cytarabine à haute-dose et à do...
    Medical condition: Leucémie aiguë myéloïde
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000344-42 Sponsor Protocol Number: AG-221-AML-004 Start Date*: 2016-01-21
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects with Late Stage Acute Myeloid Leukemi...
    Medical condition: Treatment of subjects 60 years or older with acute myeloid leukemia (AML) refractory to or relapsed after second- or third-line AML therapy and positive for an isocitrate dehydrogenase 2 (IDH2) mut...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10060558 Acute myeloid leukemia recurrent LLT
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Temporarily Halted) GB (GB - no longer in EU/EEA) ES (Ongoing) DK (Ongoing) BE (Completed) AT (Completed) CZ (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005794-29 Sponsor Protocol Number: GFM-BAR-C-2005 Start Date*: 2006-03-30
    Sponsor Name:Groupe français des Myélodysplasies
    Full Title: Traitement des syndromes myélodysplasiques par l'association aracytine et bortezomib
    Medical condition: Myelodysplastic syndrome (MDS) is a clonal disease of the bone marrow stem cells. The disease is frequently associated with cytopenia and/or blastosis. An evolution to an acute leukemia is not unfr...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023691-33 Sponsor Protocol Number: MUV-MEMMAT-01 Start Date*: 2011-05-05
    Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Kinder- und Jugendheilkunde
    Full Title: A Phase II study of metronomic and targeted anti-angiogenesis therapy for children with recurrent/progressive medulloblastoma, ependymoma and ATRT
    Medical condition: Recurrent/progressive medulloblastoma, ependymoma and ATRT
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Ongoing) SE (Restarted) CZ (Ongoing) DK (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003025-28 Sponsor Protocol Number: TUD-RELAX1-070 Start Date*: Information not available in EudraCT
    Sponsor Name:Technische Universität Dresden
    Full Title: Phase-I/II trial for relapsed or refractory AML patients combining cytarabine and mitoxantrone with venetoclax
    Medical condition: Patients 18-75 years with acute myeloid leukaemia (AML) at first or second relapse after intensive chemotherapy including allogeneic stem cell transplantation or primary refractory to standard indu...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-012758-18 Sponsor Protocol Number: COALL09-05-04 Start Date*: 2010-09-09
    Sponsor Name:Universitätsklinikum Hamburg-Eppendorf
    Full Title: A randomized multi-center treatment study (COALL 08-09) to improve the survival of children with acute lymphoblastic leukemia on behalf of the German Society of Pediatric Hematology and Oncology
    Medical condition: acute lymphoblastic leukemia in children and adolescents 1 to ≤ 18 years of age
    Disease: Version SOC Term Classification Code Term Level
    12.1 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-000279-16 Sponsor Protocol Number: TRALG 1/02 Start Date*: 2007-06-07
    Sponsor Name:Sahlgrenska University Hospital
    Full Title: Phase III Clinical Study of Allogeneic Stem Cell Transplantation with Reduced Conditioning (RICT) versus Best Standard of Care in Acute Myeloid Leukemia (AML) in First Complete Remission
    Medical condition: Acute myeloid leukemia in first complete remission
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-010951-28 Sponsor Protocol Number: CLTR0308-205 Start Date*: 2009-09-30
    Sponsor Name:Celator Pharmaceuticals, Inc
    Full Title: Phase IIB, multicenter, randomized, open-label trial of CPX-351 (Cytarabine:Daunorubicin) liposome injection versus intensive salvage therapy in adult patients ≤ 60 years old with AML in first rela...
    Medical condition: Acute myeloid leukemia recurrent (Acute Myeloid Leukemia in First Relapse Following an Initial CR >1 Month Duration).
    Disease: Version SOC Term Classification Code Term Level
    12.0 10060558 Acute myeloid leukemia recurrent LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004421-24 Sponsor Protocol Number: LUMC2012-02 Start Date*: 2014-04-14
    Sponsor Name:Leiden Universtity Medical Center
    Full Title: Sequential FLAMSA chemotherapy and T cell depleted reduced intensity conditioning allogeneic stem cell transplantation (TCD FLAMSA-RIC alloSCT) in elderly acute myeloid leukemia and high risk myelo...
    Medical condition: acute myeloid leukemia and high risk myelodysplasia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-006084-23 Sponsor Protocol Number: P060239 Start Date*: 2007-05-28
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Etude multicentrique, randomisée , de phase II évaluant l'association méthotrexate et témozolomide (MT) à l'association méthotrexate, procarbazine, vincristine et cytarabine (MPV-A) dans le traitem...
    Medical condition: Lymphome Primitif du Système Nerveux Central (LPSNC) chez le sujet âgé
    Disease: Version SOC Term Classification Code Term Level
    8.1 10007953 Lymphome Primitif du Système Nerveux Central PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000383-18 Sponsor Protocol Number: LAL1913 Start Date*: 2014-05-20
    Sponsor Name:G.I.M.EM.A. Gruppo Italiano Malattie EMatologiche dell'Adulto
    Full Title: National Treatment Program of Philadelphia Chromosome-negative Adult Acute Lymphoblastic Leukemia with Pegylated Asparaginase Added to a Lineage-Targeted Risk- and Minimal Residual Disease-Oriented...
    Medical condition: National Treatment Program of Philadelphia Chromosome-negative Adult Acute Lymphoblastic Leukemia with Pegylated Asparaginase added to a Lineage-Targeted Risk- and Minimal Residual Disease-Oriented...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-002885-34 Sponsor Protocol Number: CHIP-AML22/Master Start Date*: 2023-03-17
    Sponsor Name:Princess Máxima Center
    Full Title: CHIP-AML22 Master protocol: An open label complex clinical trial in newly diagnosed pediatric de novo AML patients – a study by the NOPHO-DB-SHIP consortium
    Medical condition: Acute Myeloid Leukemia
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004579-11 Sponsor Protocol Number: GO40871 Start Date*: 2020-01-21
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE I/II, MULTICENTER, OPEN-LABEL, MULTI-ARM STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ACTIVITY OF IDASANUTLIN IN COMBINATION WITH EITHER CHEMOTHERAPY OR VEN...
    Medical condition: Relapsed/refractory acute leukemias (AL) and solid tumors.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000835 Acute leukemia LLT
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Ongoing) ES (Ongoing) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000705-20 Sponsor Protocol Number: EsPhALL2017/COGAALL1631 Start Date*: 2017-12-11
    Sponsor Name:Università degli Studi Milano Bicocca
    Full Title: International phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones
    Medical condition: Philadelphia positive Acute Lumphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 10022891 - Investigations 10034877 Philadelphia chromosome positive PT
    21.0 100000004864 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Ongoing) IT (Ongoing) NL (Ongoing) CZ (Ongoing) DE (Ongoing) FI (Ongoing) BE (Ongoing) SE (Ongoing) PL (Ongoing) DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005493-10 Sponsor Protocol Number: MB-106 Start Date*: 2022-03-22
    Sponsor Name:Moleculin Biotech, Inc.
    Full Title: Phase 1/2 Study of Liposomal Annamycin in Combination with Cytarabine for the Treatment of Subjects with Acute Myeloid Leukemia (AML).
    Medical condition: Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004498-29 Sponsor Protocol Number: 20190360 Start Date*: 2022-01-13
    Sponsor Name:Amgen Inc.
    Full Title: Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor...
    Medical condition: Newly Diagnosed Philadelphia (Ph)-negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) PT (Ongoing) SE (Ongoing) AT (Ongoing) FI (Ongoing) ES (Ongoing) DK (Ongoing) IT (Ongoing) BE (Ongoing) HU (Ongoing) BG (Ongoing) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-012432-32 Sponsor Protocol Number: IELSG 32 Start Date*: 2010-03-25
    Sponsor Name:IELSG-International Extranodal Lymphoma Study Group
    Full Title: Randomized phase II trial on primary chemotherapy with high-dose methotrexate and high-dose cytarabine with or without thiotepa, and with or without rituximab, followed by brain irradiation vs. h...
    Medical condition: newly diagnosed primary CNS lymphoma in immunocompetent patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036685 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) DE (Completed) GB (GB - no longer in EU/EEA) DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-003075-37 Sponsor Protocol Number: NLG-LBC-04 Start Date*: 2004-12-20
    Sponsor Name:Nordic Lymphoma Group
    Full Title: CHOEP-14 + rituximab with CNS prophylaxis in patients less than 65 years with Diffuse Large B-Cell Lymphoma/Follicular Lymphoma grade III, stage II-IV with risk factors (age adjusted IPI) ≥ 2. A ph...
    Medical condition: 18-64 year old patients having primary diffuse large B-cell lymphoma (DLBCL) with risk factors (age adjusted IPI≥2), or follicular lymphoma grade III
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2023 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA